{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003197","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.745856+00:00","generated_at":"2026-06-07T01:30:04.212981+00:00","sec_items":["3.01","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024","bullets":["FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.","Phase 1 study first participant enrollment expected in H1 2024; pre-clinical data showed enhanced anti-tumor activity.","Nasdaq granted extension until May 8, 2024 to regain compliance with $2.5M stockholders' equity requirement, conditional on capital raise.","Stockholders' equity was $311,016 as of Sep 30, 2023, below the $2.5M minimum; alternative standards not met.","Failure to regain compliance by May 8, 2024 may lead to delisting; company has right to appeal."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003197","json":"https://secwatch.observer/filing/0000950170-24-003197.json","markdown":"https://secwatch.observer/filing/0000950170-24-003197.md","text":"https://secwatch.observer/filing/0000950170-24-003197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/0000950170-24-003197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/crbp-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:30:04.212981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74230619f16d0c7e4cb10c75d99e9df03cc152c0","claim":"Corbus Pharmaceuticals Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $311,016, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, was below the required minimum of $2.5 million, and because, as of November 9,","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/0000950170-24-003197-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}